BioNTech and DualityBio form global strategic partnership
Focus on accelerated development of differentiated antibody-drug conjugates therapeutics for solid tumors
04-Apr-2023 -
BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. (DualityBio), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, announced that the companies have ...
antibody-drug conjugate
BioNTech
cancer
+1